February 4, 2022 -- Intellia Therapeutics has acquired Rewrite Therapeutics, a private biotechnology company focused on advancing novel DNA writing technologies. The acquisition further expands Intellia's genome editing toolbox by adding a platform that is highly complementary to its existing CRISPR-Cas9 and base editing technologies.
As part of the transaction, Intellia will pay Rewrite shareholders $45 million in an upfront payment and an additional $155 million in prespecified research and regulatory approval milestones through a mix of Intellia common stock and cash. Additional financial details were not disclosed.
Intellia Therapeutics, a clinical-stage genome editing company, is developing novel therapeutics leveraging CRISPR-based technologies. Rewrite Therapeutics' proprietary and versatile DNA writing platform enables a range of novel genome editing strategies.
Copyright © 2022 scienceboard.net